• Explore /
  • Poster
  • / LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA <em>RET</em> fusion-positive (<em>RET</em>+) NSCLC.

LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.

Abstract Poster

Authors

null

Theresa Bayt

Eli Lilly and Co, Indianapolis, IN

Theresa Bayt , Jonathan W. Goldman , Jacob Sands , Andreas Hallqvist , Hye Ryun Kim , Guoping Li , Lin Wu , Weiji Su , Xue-Ning Yang , Maximilian Hochmair

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Breakthrough

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B

Track

Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics

Sub Track

Advanced Disease

Clinical Trial Registration Number

NCT04819100

Citation

J Clin Oncol 42, 2024 (suppl 23; abstr TPS216)

DOI

10.1200/JCO.2024.42.23_suppl.TPS216

Abstract #

TPS216

Poster Bd #

L7

Abstract Disclosures

Similar Posters

First Author: Makoto Nishio

First Author: Igor Odintsov

First Author: Leeseul Kim

Poster

2024 ASCO Breakthrough

Intracranial outcomes of 1L selpercatinib in advanced <em>RET</em> fusion-positive NSCLC: LIBRETTO-431 study.

Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.

First Author: Minji Uh